REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 19,608 Shares of Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 19,608 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $11.04, for a total transaction of $216,472.32. Following the transaction, the insider directly owned 213,009 shares in the company, valued at approximately $2,351,619.36. This represents a 8.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Steve Pakola also recently made the following trade(s):

• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Price Performance

Shares of RGNX stock opened at $13.09 on Thursday. The business has a 50-day moving average of $8.12 and a 200 day moving average of $9.91. REGENXBIO Inc. has a 1-year low of $5.45 and a 1-year high of $16.19. The stock has a market capitalization of $676.73 million, a PE ratio of -2.34 and a beta of 1.04.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The firm had revenue of $6.39 million during the quarter, compared to analysts’ expectations of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. Analysts anticipate that REGENXBIO Inc. will post -3.69 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Barclays dropped their target price on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, May 15th. Bank of America lowered their price target on REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of REGENXBIO in a report on Wednesday. Leerink Partners boosted their target price on REGENXBIO from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Monday, June 22nd. Finally, Robert W. Baird upped their target price on REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.82.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently modified their holdings of RGNX. Aquatic Capital Management LLC bought a new position in shares of REGENXBIO in the 3rd quarter worth approximately $37,000. Captrust Financial Advisors bought a new stake in shares of REGENXBIO during the second quarter valued at approximately $85,000. Entropy Technologies LP purchased a new stake in REGENXBIO in the first quarter worth $87,000. Prudential Financial Inc. purchased a new stake in REGENXBIO in the second quarter worth $87,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in REGENXBIO by 271.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 7,924 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.